Showing 2701-2710 of 5909 results for "".
- Hoya Surgical Optics Introduces On-Demand Platform Qube Pro Powered by Eyeflexahttps://modernod.com/news/hoya-surgical-optics-introduces-on-demand-platform-qube-pro-powered-by-eyeflexa/2478514/Hoya Surgical Optics obtained CE Mark for “Qube pro powered by eyeflexa,” a technology that can support both cataract and vitreoretinal surgery. Eyeflexa is a multi-upgrade platform designed to evolve with the changing needs of ophthalmic surgeons, according to a company news r
- Avellino Introduces Multiplex Respiratory Panel for Simultaneous Detection of COVID-19 and Influenzahttps://modernod.com/news/avellino-introduces-multiplex-respiratory-panel-for-simultaneous-detection-of-covid-19-and-influenza/2478505/Avellino announced that the company has developed a novel multi-panel RT-PCR-based virus assay, AvellinoCoV2-Respiratory, which has been validated following the FDA’s Policy for Diagnostics Testing in Laboratories Certified to Perform High-Complexity Testing CLIA guidelines. The AvellinoCoV
- Vision Impairment Tied to Less Use of Cancer Screenings by Older Adultshttps://modernod.com/news/vision-impairment-tied-to-less-use-of-cancer-screenings-by-older-adults/2478491/Older adults with vision impairment are less likely to receive recommended breast and colon cancer screenings than peers without vision problems, a U.S. study suggests, according to a Reuters report. Researchers examined data from
- Ocular Therapeutix and AffaMed Therapeutics Announce License Agreement for Dextenza and OTX-TIC in Asiahttps://modernod.com/news/ocular-therapeutix-and-affamed-therapeutics-announce-license-agreement-and-collaboration-for-dextenza-and-otx-tic-in-asia/2478479/Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. Dextenza is currently approved in the U.S. for the treatment of post-surgical ocul
- CVS Pharmacy Launches QuickRenew At-Home Contact Lens Prescription Renewal Toolhttps://modernod.com/news/cvs-pharmacy-launches-quickrenew-at-home-contact-lens-prescription-renewal-tool/2478465/CVS Pharmacy announced the launch of QuickRenew, an online contact lens prescription renewal tool currently available on the
- Blanchard Contact Lenses Adds Paragon CRT to Product Portfoliohttps://modernod.com/news/blanchard-contact-lenses-adds-paragon-crt-to-product-portfolio/2478464/Blanchard Contact Lenses announced that it has expanded its product portfolio in the United States to include Paragon CRT and Paragon CRT Dual Axis ortho-k lenses. Paragon CRT and Paragon CRT Dual Axis are reverse geometry corneal lenses manufactured in high-Dk gas permeable lens material
- Bausch + Lomb Introduces SimplifEYE IOL Delivery System for Envista Toric and Monofocal Preloaded IOLshttps://modernod.com/news/bausch-lomb-introduces-simplifeye-iol-delivery-system-for-envista-toric-and-monofocal-preloaded-iols/2478461/Bausch + Lomb announced the introduction of the SimplifEYE IOL delivery system, which is available exclusively for the enVista MX60PL and the enVista toric MX60PT, the first preloaded toric IOL available in the United States. “Surgeons recognize that using a preloaded IOL system can stream
- Nova Eye Medical Establishes “AlphaRET” to Fulfill the Commercial Development of 2RThttps://modernod.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/Nova Eye Medical has announced the reorganization of its 2RT assets via the establishment of AlphaRET Pty Ltd. Establishing AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the company to better concentrate its commercialization efforts for 2RT, and delineate th
- Nicox Selects Development Candidate in a New Class of NO-Mediated IOP Lowering Agentshttps://modernod.com/news/nicox-selects-development-candidate-in-a-new-class-of-no-mediated-iop-lowering-agents/2478452/Nicox SA announced that it has selected a new development candidate, NCX 1728, from its proprietary research program focused on nitric oxide (NO)-mediated IOP lowering agents. An analog of this molecule has demonstrated positive results in ocular hypertensive
- Outpatient Visits Rebound for Most Specialties to Pre-COVID Levelshttps://modernod.com/news/outpatient-visits-rebound-for-most-specialties-to-pre-covid-levels/2478438/After taking a nosedive during the initial wave of the COVID-19 pandemic, then rising and plateauing, weekly outpatient visits in the United States have rebounded and now slightly exceed levels seen in late February, according to new data, Medscape